Related Experiment Video
Updated: May 29, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
[Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis]
Wang Di1, Yan Chang, Yu-Jing Wu
1Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immunopharmacology of Education Ministry of China, Hefei 230032, China.
Sheng Li Ke Xue Jin Zhan [Progress in Physiology]
|September 22, 2011
Summary
Targeting B cells offers a promising therapeutic strategy for rheumatoid arthritis (RA), an autoimmune disease with limited treatment options. Emerging biologic agents show efficacy in RA and animal models, highlighting B cell-based therapies.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Context:
- Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease with unknown pathogenic mechanisms and a lack of safe, effective treatments.
- B cells play a critical role in RA pathogenesis, making them a key target for novel therapies.
Purpose:
- To review emerging B cell-targeted biologic agents for rheumatoid arthritis therapy.
- To evaluate the efficacy of these agents in RA and relevant animal models.
Summary:
- Several classes of B cell-targeted biologics are discussed, including anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab), B lymphocyte stimulator (BLyS)-targeting agents (belimumab, atacicept), anti-CD22 monoclonal antibodies, and CD40/CD40L co-stimulation blockers.
- The efficacy of these agents has been demonstrated in studies involving RA patients and animal models.
Impact:
- B cell-targeted therapy represents a promising strategy for managing rheumatoid arthritis.
- Further research and clinical application of these agents could lead to improved treatment outcomes for RA patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...